Financing - December 13, 2016
Nordic Nanovector raised 500 MNOK
Nordic Nanovector has raised MNOK 500 in gross proceeds through a private placement of 4,374,244 new shares. Nordic Nanovector intends to use the net proceeds to fund a Phase 2 combination study of Betalutin® and Rituximab CD20, fund a Phase 1 study and GMP manufacturing for 177Lu-conjugated chimeric antibody (anti-CD37 ARC), develop new proprietary antibody […]
Collaboration - October 27, 2016
Nordic Nanovector, Heidelberg Pharma collaborate
Nordic Nanovector has entered into a collaboration with Heidelberg Pharma, a subsidiary of biopharmaceutical company WILEX specializing in the development of antibody-drug conjugates (ADCs), to develop novel ADCs for treating leukaemias. This collaboration is part of Nordic Nanovector’s strategy to develop its pipeline of targeted therapies to include antibody products conjugated to anti-cancer compounds that […]
Agreement - October 10, 2016
Nordic Nanovector in new collaboration
Nordic Nanovector has entered into a collaboration with LegoChem Biosciences, a South Korea-based biopharmaceutical company, to develop novel CD37-targeting antibody-drug conjugates (ADCs) for the treatment of leukaemias. Leukemias are orphan diseases with a significant unmet medical need, representing a growing market estimated to be worth over USD 5 billion by 2024. This collaboration supports Nordic […]
Drug Development Pharma - September 6, 2016
New findings from Nordic Nanovector
Nordic Nanovector announces that two papers recently published in The Journal of Nuclear Medicine have shown that pre-dosing with the anti-CD37 antibody lilotomab (previously referred to as HH1), prior to injection with Betalutin (177Lu-lilotomab) reduces haematological toxicity without adversely impacting the amount of radiation absorbed by the tumour. Betalutin is a novel anti-CD37 antibody-radionuclide-conjugate (ARC) […]
Clinical Trials - August 19, 2016
Nordic Nanovector completes patient recruitment
Nordic Nanovector announces that the first cohorts of both Arm 3 and 4 of the expanded Lymrit 37-01 clinical study with Betalutin have been completed. Betalutin is a novel anti-CD37 targeting Antibody Radionuclide Conjugate in development for the treatment of major types of non-Hodgkin lymphoma (NHL), including Follicular Lymphoma (FL). Arm 3 is investigating the […]
Collaboration - June 28, 2016
Nordic Nanovector, AREVA collaborates
Nordic Nanovector and AREVA Med, the AREVA medical subsidiary developing lead-212 (212Pb) based cancer therapies, have entered into a collaboration agreement to investigate the potential of a 212Pb-conjugated anti-CD37 antibody for the treatment of leukaemias. Leukemias are orphan diseases with a significant unmet medical need. Prevalent relapsed AML and CLL patients are more than 60,000 […]
